Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 2
Submit an article Journal homepage
227
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant

Hongnan MoDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Yuankai ShiDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, ChinaCorrespondence[email protected]
,
Xiaohong HanDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Peng LiuDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Jianliang YangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Changgong ZhangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Shen YangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Yan QinDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Lin GuiDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Youwu ShiDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Jiarui YaoDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
,
Liya ZhaoDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
&
Shuxiang ZhangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chaoyang, Beijing, China
 show all
Pages 515-517 | Received 16 Mar 2014, Accepted 27 Apr 2014, Published online: 15 Jul 2014

References

  • National Comprehensive Cancer Network. 2014 NCCN Clinical Practical Guidelines in Oncology. Non-Hodgkin's Lymphomas. Available from: www.nccn.org
  • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
  • Vaidya R, Witzig TE. Prognostic factors for diffuse large B cell lymphoma in the R(X)CHOP era. Ann Oncol 2014 Mar 13. [Epub ahead of print]
  • Tadmor T, Bari A, Sacchi S, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era. Haematologica 2014;99:125–130.
  • Li YL, Pan YY, Jiao Y, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol 2014;93:617–626.
  • Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012;17:871–880.
  • Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14 + HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011;117:872–881.
  • Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012;60:313–319.
  • Herishanu Y, Kay S, Sarid N, et al. Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. Leuk Res 2013;37:1222–1228.
  • Thoma MD, Huneke TJ, DeCook LJ, et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012;18:600–607.
  • Watanabe R, Tomita N, Kishimoto K, et al. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res 2013;37:1208–1212.
  • Porrata LF, Ristow K, Markovic SN. Absolute monocyte count at diagnosis and survival in mantle cell lymphoma. Br J Haematol 2013;163:545–547.
  • Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011;25:1502–1509.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.